DigmBio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Investors
-
10
DigmBio General Information
Description
Developer of a novel dementia treatment designed to target the T1R3 GPCR. The company offers small-molecule drug discovery, therapeutic research, preclinical development, target identification, and clinical development capabilities to develop therapies for cancer and neurological disorders, enabling pharmaceutical companies, research organizations, and healthcare providers to advance treatments for complex diseases and support the development of new medicines.
Contact Information
Website
www.digmbio.comCorporate Office
- Number 901, 9-22, Pangyo-ro, 255 beon-gil, Bundang-gu
- Seongnam, Gyeonggi 13486
- South Korea
Corporate Office
- Number 901, 9-22, Pangyo-ro, 255 beon-gil, Bundang-gu
- Seongnam, Gyeonggi 13486
- South Korea
DigmBio Timeline
DigmBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 29-Jul-2026 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 25-Mar-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 01-Oct-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 01-Mar-2021 | Completed | Startup | |||
| 2. Angel (individual) | 01-May-2020 | $245K | $245K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
DigmBio Signals
DigmBio Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cornerstone Investment Partners | Asset Manager | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority | ||
| Meritz Securities | Investment Bank | Minority | ||
| Myriad Life Sciences | Accelerator/Incubator | Minority | ||
| Partners Investment | Venture Capital | Minority |
DigmBio FAQs
-
When was DigmBio founded?
DigmBio was founded in 2020.
-
Where is DigmBio headquartered?
DigmBio is headquartered in Seongnam, South Korea.
-
What is the size of DigmBio?
DigmBio has 10 total employees.
-
What industry is DigmBio in?
DigmBio’s primary industry is Drug Discovery.
-
Is DigmBio a private or public company?
DigmBio is a Private company.
-
What is DigmBio’s current revenue?
The current revenue for DigmBio is .
-
How much funding has DigmBio raised over time?
DigmBio has raised $10.6M.
-
Who are DigmBio’s investors?
Cornerstone Investment Partners, Industrial Bank of Korea, Meritz Securities, Myriad Life Sciences, and Partners Investment are 5 of 10 investors who have invested in DigmBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process